Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752358 · ClinicalTrials.gov registry record · Phase 2
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
A Phase 2 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04752358 is a Phase 2 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 3 participants.
The verdict
NCT04752358, a Phase 2 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.
Interventions
- GENETIC Autologous genetically modified ADP-A2M4CD8 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752358
The ClinicalTrials.gov registry entry for NCT04752358 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous genetically modified ADP-A2M4CD8 cells is the first listed.
NCT04752358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04752358 about?
NCT04752358 is a clinical study titled "ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)". This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.
What is the current status of trial NCT04752358?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-09-15. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04752358?
The interventions under investigation include: Autologous genetically modified ADP-A2M4CD8 cells (GENETIC).
Who is sponsoring clinical trial NCT04752358?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.